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Abstract
Streptococcus pneumoniae is a common cause of infection in both HIV positive patients and those with complement
deficiencies. We hypothesised that HIV positive individuals might exhibit reduced opsonisation of pneumococcus with
complement due to reduced levels of S. pneumoniae specific IgG. We discovered no difference in C3 deposition on S.
pneumoniae between HIV positive or negative individuals, and furthermore C3 deposition remained unchanged as HIV
progressed towards AIDS. We found no correlation between C3 deposition on S. pneumoniae and CD4 cell count in HIV
infected individuals. Hence we have demonstrated no failure of complement immunity in HIV positive patients.
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Introduction
Streptococcus pneumoniae is an important cause of morbidity and
mortality in patients infected with HIV (Human Immunodeficien-
cy Virus) and furthermore it is one of the most common bacterial
pathogens to affect HIV positive adults and children [1,2]. There
are multiple reasons for increased S. pneumoniae linked disease in
HIV positive patients, including decreased carriage, decreased
CD4 (Cluster of Differentiation 4) mediated TH17 immunity, and
altered IgG function. The polyclonal hypergammaglobulinaemia
which occurs in HIV infected individuals due to non-specific
activation of B lymphocytes induces a predominately IgG1
elevation [3]. However, IgG2 is often the predominant subclass
of antibody produced in response to the pneumococcal polysac-
charide capsule, which surrounds S. pneumoniae and is both the
most important virulence factor for this pathogen and the target of
current vaccine preparations [4,5]. The polyclonal hypergamma-
globulinaemia results in a relatively low level of capsule specific
IgG in HIV infected individuals but absolute levels are not
significantly different [6,7]. IgG function has been shown to be
impaired in HIV serum [8], with the mechanism for this
potentially including VH3 gene repertoire deletion [9] or splenic
architecture changes [10]. IgG is a potent activator of the classical
complement pathway, leading to increased deposition of C3, the
central complement component, on the bacterial cell surface [11].
Complement mediated immunity has been demonstrated to be
important for opsonisation of the bacteria for neutrophil
phagocytosis and in systemic clearance of S. pneumoniae infection
[12]. Furthermore, individuals with chronic conditions which
result in complement deficiencies, such as systemic lupus
erythematosus and sickle cell anemia, also show increased
incidence of invasive pneumococcal disease [13,14]. However,
individuals infected with HIV are known to have comparable
levels to non-infected individuals of C3 and C4 complement
components [15,16]. It is unclear whether there is a functional
deficiency in complement mediated immunity to S. pneumoniae in
HIV but C3 deposition in HIV positive individuals could be
affected by reduced complement activation due to decreased
percentage of pneumococcal specific IgG or altered IgG function.
We hypothesized that the relatively high incidence of pneumo-
coccal disease in HIV infected individuals might be due to a low
level of complement deposition on the bacterial surface due to the
relatively low level of specific IgG against S. pneumoniae. Using D39
S. pneumoniae as a reference strain we measured C3 deposition on
the bacterial cell surface using serum samples from HIV negative
and HIV positive individuals collected serially over time.
Materials and Methods
Samples, Patients, Ethics
Subject recruitment and sample collection Adult Malawians
were recruited by advertisement and gave written informed
consent to participate in a study of pulmonary immune responses
to infection. This study included serum sampling and HIV testing.
This study was approved by the Liverpool School of Tropical
Medicine Research Ethics Committee and the College of
Medicine Research Ethics Committee of the University of Malawi.
Patients attended recruitment clinic when venous blood was
collected and samples were transferred on ice immediately to the
laboratory and centrifuged to remove the cellular pellet.
Supernatant fluid and serum obtained from venous blood were
stored at 280uC for future assay.
A patient cohort of 31 HIV positive and 20 HIV negative
individuals was established from the Malawian cohort. The HIV
infected individuals were not receiving HAART (Highly Active
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were followed over 5 years with repeat samples obtained from the
same individuals as their disease progressed. These samples were
collected in the period 2001–2005 before anti-retroviral therapy
(ART) became available in Malawi. In 2005, all volunteers known
to be HIV positive were referred to the new ART clinic together
with their CD4 count and clinical files where they received
expedited care. samples from HIV uninfected control subjects
were selected for this study from archived samples collected during
the same period (2001–2005) in the same location and by the same
strategy (public advertisement) as the HIV positive samples. The
cohort of subjects volunteered for wider studies of susceptibility to
pneumococcal infection which included bronchoscopy and related
work on blood samples.
Bacteria
S, pneumoniae D39 were cultured at 37uCi n5 %C O 2 on blood
agar plates or in Todd-Hewitt broth supplemented with 0.5%
yeast extract to OD580 nm 0.4 (approximately 10
8 CFU/ml) and
stored at –70uC in 10% glycerol as single-use aliquots.
C3b/iC3b Binding Assay
C3b/iC3b deposition on the bacteria surface was measured
using 2610
6 cfu of D39 S. pneumoniae and incubating in 10 ml 10%
human serum for 20 minutes at 37uC. C3b/iC3b was measured
using a previously described flow cytometry assay and fluorescein
isothiocyanate (FITC) conjugated polyclonal anti-human C3 Ab
(ICN) [17,18]. Results of the complement binding assay are
presented as a mean fluorescence index [FI (Fluorescent Index),
proportion of positive bacteria expressed as a percentage
multiplied by the geometric mean MFI] in arbitary units
[12,17,18]. Serum samples were analysed blind to the HIV status
of the individual tested.
Statistics
Results presented as medians (IQRs) were compared using the
using the Kruskal Wallis test with Dunn’s multiple comparison test
(multiple groups) or Mann Whitney U test (for two groups) and
presented as box and whisker plots. Correlations were analysed
using Pearson’s Correlation Co-efficient. Data are representative
of results obtained with repeated assays with four replicas per
condition.
Results
The patient cohort details are listed in Table 1.
Table 1. Patient cohort table.
HIV Positive HIV Negative P-value
Number 23 15 -
Gender (M:F) 14:9 12:3 0.215{
Age Mean 6 SD 32.1768.14 30.93611.30 0.696*
CD4 Count Median
(Range)
200 (0–569) 825 (456–1049) ,0.0001**
Previous Pneumococcal
Disease Incidence
6 0 0.031{
P-values represent the results of Student t tests (*), Mann-Whitney U-Tests (**)
or chi-squared tests ({).
doi:10.1371/journal.pone.0008902.t001
Figure 1. The effect of HIV infection on C3b/iC3b deposition on
Streptococcus pneumoniae. (A) Fluorescent Index (FI) of C3b/iC3b
deposition on D39 S. pneumoniae incubated in 20% human serum from
HIV positive (open bars, n=23) or negative individuals (slashed bars,
n=15), P=0.037 Mann-Whitney U test. (B). FI of C3b/iC3b deposition on
D39 incubated in 20% serum from HIV positive (open bars) or negative
(slashed bars) individuals over time. Samples 1, 2 and 3 were collected
sequentially from individuals. ANOVA P=0.42) (C) C3b/iC3b deposition on
D39 from HIV positive individuals was plotted against the CD4 cell count
for that individual, Pearson’s correlation co-efficient P=0.382R
2=0.029).
doi:10.1371/journal.pone.0008902.g001
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collected from HIV infected and non-infected individuals to
opsonise D39 S. pneumoniae (Figure 1A). To investigate if the ability
of serum from HIV positive patients deteriorated over time we
analysed the amount of C3 deposition in serum collected from
individuals with a minimum of 6 months between repeat samples
as they progressed through the cohort. This was compared to
serum samples collected over the same time period in the same
cohort from non HIV infected patients. There was no detectable
change in C3b/iC3b deposition over time in HIV negative
individuals (Figure 1B). There was also no difference in C3b/iC3b
deposition on S. pneumoniae in serum obtained from HIV positive
individuals over time, suggesting no change in opsonisation as
HIV progresses to AIDS.
We then examined if there was a relationship between C3b/
iC3b deposition on S. pneumoniae and the CD4 cell count (which is
a marker of HIV severity) in our HIV positive cohort (Figure 1C).
We found no detectable correlation between complement
deposition and CD4 count, indicating that there was no change
in the ability of patients to opsonise S. pneumoniae in relation to the
severity of HIV.
Discussion
Streptococcus pneumoniae is the most common cause of bacterial
pneumonia in HIV infected patients, with HIV infected children
showing a disease incidence of approximately 10–100 times that of
their HIV negative peers [19]. It is likely that S. pneumoniae disease
results from an interaction between host defences and bacterial
virulence factors, and a major component of host immunity to S.
pneumoniae is the complement system [12,18]. Complement is
activated through one of three major routes, known as the
classical, alternative and mannose-binding lectin pathways. Of
particular importance in host immunity to S. pneumoniae is the
classical pathway, which is activated by antibody as well other
opsonins [12,18]. Polyclonal hypergammaglobulinaemia which
occurs in HIV infected individuals results in a relatively low serum
capsule specific IgG but absolute antibody levels are not
significantly different [6,7]. Both the level of capsule specific IgG
and the classical complement pathway (through which antibody
exerts an effect on the complement system) are important to host
immunity to S. pneumoniae [12,20,21]. We therefore hypothesised
that a functional deficiency in the classical complement pathway
due to reduced activation via IgG would lead to reduced
opsonisation with C3 on the S. pneumoniae bacterial cell surface
in HIV infected individuals compared to seronegative controls.
Our results detected no impairment in the ability of serum
isolated from HIV positive individuals to opsonise a serotype 2
strain of S. pneumoniae compared to serum obtained from HIV
negative controls. Whilst the median level of C3b/iC3b deposition
for both patient populations remained approximately the same,
there was increased variation in C3b/iC3b deposition on the
bacterial cell surface when opsonised with serum from HIV
individuals, which may perhaps be accounted for by differences in
opsonising ability as HIV progresses towards AIDS (Acquired
Immune Deficiency Syndrome). However there was no reduction
in the relative amount of C3b/iC3b deposited on S. pneumoniae
between serial serum samples obtained from the same individuals,
indicating that there was no change in the ability of the serum to
act as a opsonin as HIV disease progresses. Furthermore there was
also no correlation between the CD4 count of the patient and the
ability of the serum to opsonise S. pneumoniae with complement.
A clinically relevant depletion of C3 is seen in SLE, where in
active disease without treatment, there is a depletion of 23.2% of
the normal values [22]. Our study would have a 78% power to
detect this. For inactive SLE, with treatment, there is a depletion
to 62.8% of normal values [22], where our study would have a
27.9% power to pick up this change. In addition, there would be a
hypothesised decrease in the C3 binding for HIV serum, but this
was not the case, and instead there seems to be a slight increase in
the binding, albeit not significant.
In conclusion, we found no detectable difference in the ability of
serum obtained from HIV to opsonise S. pneumoniae with C3b/
iC3b infected individuals compared to seronegative control
individuals. We also found no reduction in deposition of C3b/
iC3b on the bacterial cell surface as HIV progressed towards
AIDS in our cohort. Hence, in our patient cohort there is no
failure in complement deposition on pneumococcus as HIV
becomes more severe and progresses to AIDS. Therefore we
conclude that the polyclonal hypergammaglobulinaemia which
leads to a decrease in the level of capsular specific IgG against
pneumococcus does not result in a loss of function in complement
deposition on S. pneumoniae.
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